According to WHO, pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. The major aim of pharmacovigilance systems is the early detection of unknown, drug safety problems, detection of increases in frequency, identification of risk factors quantifying risks, and preventing of patients from being affected unnecessarily.
With the ultimate objective of patient safety first, Qpharma continuously complies with Good Pharmacovigilance Practice (GPP), to assure standards and innovations in the collection, management, analysis, and use of medication safety information. We share the risks and benefits with the entire team, both internal and external partners, through structured governance and communications at every level, and endeavour to meet the evolving global and local regulatory requirements.
At Qpharma, reducing error and harm from medicines through safe and quality use is an important element of our work and is helping us to achieve our objective of leading and coordinating safety and quality improvements in healthcare.
With the aim to enhance patient care and patient safety in relation to the use of medicines we work to:

